BioLattice is a startup based in the United States.
BioLattice develops an engineered, shelf-stable corneal tissue substitute called CorneaClear™ as an alternative to donor corneas for corneal transplants, aiming to reduce rejection and eliminate cold-chain storage requirements.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.